intervention. Dual inhibitors and bispecific antibodies simultaneously targeting IL17A and IL17F are under investigation in different clinical studies to treat psoriasis and psoriatic arthritis [14], or to prevent pathological bone formation, which may be helpful in the treatment of ankylosing spondylitis...
Discontinuation due to mild adverse events within one year of treatment occurred in 12 patients (2.4%). Causes were attributed to ineffectiveness (four patients), facial redness dermatitis (three patients), blepharoconjunctivitis (four patients), and psoriasis (three patients). Two patients discontinue...